Cantor Fitzgerald Brokers Reduce Earnings Estimates for SLDB

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Stock analysts at Cantor Fitzgerald cut their FY2024 earnings per share estimates for Solid Biosciences in a research report issued to clients and investors on Monday, November 18th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings per share of ($2.85) for the year, down from their previous estimate of ($2.54). The consensus estimate for Solid Biosciences' current full-year earnings is ($2.81) per share.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.12).

A number of other analysts also recently issued reports on the stock. Barclays reduced their price target on shares of Solid Biosciences from $18.00 to $15.00 and set an "overweight" rating on the stock in a report on Wednesday, August 14th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Solid Biosciences in a report on Thursday, November 7th. Chardan Capital reissued a "buy" rating and set a $15.00 price target on shares of Solid Biosciences in a research note on Monday, November 11th. JPMorgan Chase & Co. cut their price target on Solid Biosciences from $15.00 to $12.00 and set an "overweight" rating for the company in a report on Tuesday, November 12th. Finally, William Blair raised Solid Biosciences to a "strong-buy" rating in a report on Friday, August 30th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $15.14.

Solid Biosciences Price Performance

SLDB stock opened at $4.96 on Thursday. The company's fifty day moving average price is $6.37 and its 200-day moving average price is $7.53. Solid Biosciences has a one year low of $2.32 and a one year high of $15.05.

Institutional Investors Weigh In On Solid Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC bought a new position in shares of Solid Biosciences during the 1st quarter valued at approximately $23,935,000. Artal Group S.A. boosted its stake in Solid Biosciences by 175.0% during the first quarter. Artal Group S.A. now owns 2,500,000 shares of the company's stock worth $33,300,000 after buying an additional 1,590,781 shares during the period. Millennium Management LLC increased its position in Solid Biosciences by 135.7% during the second quarter. Millennium Management LLC now owns 1,728,065 shares of the company's stock valued at $9,798,000 after acquiring an additional 994,984 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Solid Biosciences by 283.9% in the first quarter. Vanguard Group Inc. now owns 1,244,575 shares of the company's stock valued at $16,578,000 after acquiring an additional 920,404 shares during the period. Finally, RA Capital Management L.P. lifted its holdings in shares of Solid Biosciences by 26.4% in the 1st quarter. RA Capital Management L.P. now owns 4,330,446 shares of the company's stock worth $57,682,000 after acquiring an additional 904,160 shares during the last quarter. 81.46% of the stock is currently owned by hedge funds and other institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.